Skip to main content
9,000+ open opportunities indexed

Search Grants — Free, No Account Required

Search federal, state, and foundation grants by keyword, state, or focus area. When you find a match, apply with our AI-assisted application builder.

1,749 grants foundClear search

24 grants worth up to $3.2M match your search

Enter your email to see grant names, funders, and application links

NATIONAL LAB OPPORTUNITY

open

NASA Headquarters

OPPORTUNITY FOR THE USE OF THE INTERNATIONAL SPACE STATION BY DOMESTIC ENTITIES OTHER THAN U.S. FEDERAL GOVERNMENT AGENCIES 1.0 INTRODUCTION AND BACKGROUND The National Aeronautics and Space Administration (NASA) is operating a share of the United States accommodations on the International Space Station (ISS) as a national laboratory in accordance with Section 507 of the NASA Authorization Act of 2005 (P.L. 109-155) and to seek to increase the utilization of the ISS by other federal entities and the private sector. To facilitate and increase such utilization of the ISS, NASA is providing access to the ISS for the conduct of basic and applied research, technology development and industrial processing (collectively, R&D) to U.S. federal, state and local government entities, and to U.S. private entities (including, but not limited to, commercial firms, non-profit entities, and academic institutions) as part of the national laboratory. In preparation for the ISS post-assembly phase and during the post-assembly complete phase, NASA is seeking proposals from domestic entities other than U.S. federal government agencies for the conduct of R&D activities on the ISS as a national laboratory. NASA anticipates using its authority to enter into Space Act Agreements to support national laboratory activities, including providing necessary access to NASA facilities, personnel and technical information, however, there will be no provision of funds in connection with this opportunity. Respondents will be responsible for financing their own activities. Participation in this National Lab Opportunity will be contingent upon selection by NASA and negotiation of an appropriate Agreement between NASA and the proposer. Proposed activities should involve R&D, including, but not limited to, life sciences, sensors, communication equipment, engineering testbeds, spacecraft design and testing, or education and should demonstrate potential benefit to the public, such as development of future products and services contributing to U.S. industrial capacity and economic growth or improving STEM education. This opportunity is not exclusive; NASA, at its discretion, may negotiate with other parties for access to ISS under this opportunity. Response Date: This announcement is open through December 31, 2014. NASA will engage in ongoing review of proposals as received prior to the Response Date of December 31, 2014. NASA reserves the right to amend or withdraw this Announcement at any time prior to the Response Date. NASA will not issue paper copies of this Announcement. NASA reserves the right to select for Space Act Agreement negotiations all, some, or none of the proposals submitted in response to this Announcement. NASA provides no funding for reimbursement of proposal development costs. Material submitted in response to this Announcement will not be returned. It is the policy of NASA to safeguard all proposals as confidential and privileged information, as provided by law. NASA will not, without permission of the proposers, use the proposal contents for other than evaluation purposes. It is not NASA's intent to publicly disclose proprietary information obtained during this solicitation. To the full extent that it is protected pursuant to the Freedom of Information Act and other laws and regulations, information identified by a respondent as "Proprietary or Confidential" will be kept confidential. NASA may use contractor support personnel to assist in providing expertise regarding proposals. Any support contractor involved in the evaluation process shall be free of conflicts of interest, will be bound by appropriate non-disclosure agreements to protect proprietary and competition sensitive information. By submitting a proposal under this Announcement, the proposer is deemed to have consented to release of data in its proposal to NASA contractors supporting evaluation of proposals. 2.0 GENERAL INFORMATION Agency Name: NASA (National Aeronautics and Space Administration) Opportunity Title: Opportunity for the use of the International Space Station by Domestic Entities Other than U.S. Federal Government Agencies Response Date: Electronic Proposals must be received by December 31, 2014 at 4:30 P.M. EST via email to jason.c.crusan@nasa.gov. Proposals may be submitted at any time before the response date. Points of Contact: If you have any questions concerning this opportunity please contact: Marybeth Edeen Manager, ISS National Lab Office Telephone: 281-483-9122 Fax: 281-244-8292 Email: marybeth.a.edeen@nasa.gov Jason Crusan SOMD Agreement Manager 202-358-0635 202-358-3530 jason.crusan@nasa.gov Instrument Type(s): It is anticipated that awards under this Opportunity will be in the form of Space Act Agreements, executed under the authority of 42 U.S.C. 2473(c)(5). Selection Recommendation Committee: Government personnel from NASA, other Federal agencies, and NASA contractors may participate in the evaluation of proposals. All contractor personnel participating in the evaluation will be bound by conflict of interest provisions and appropriate non-disclosure requirements to protect proprietary information. Selection Notification Date: Selection for negotiations is anticipated to be within 60 days of receiving a proposal. Submission Instructions: All Proposals under this Announcement must be emailed to jason.c.crusan@nasa.gov. Paper submissions will not be reviewed. Proposals may be submitted at any time before the Response Date. You are encouraged to submit as early as practicable prior to the Response Date. Proposals received by the Government after the Response Date will not be accepted. If a proposer is concerned about information security during transmission NASA has the ability to accept secure transmission. Contact the Point of Contact for secure transmission requirements. Files can be submitted in MS Word, PDF, or RTF. 3.0 ELIGIBILITY INFORMATION All categories of domestic entities other than U.S. federal government agencies are eligible to submit proposals in response to this Announcement. NASA will not consider proposals which do not include a domestic entity as the lead proposer. 4.0 PROPOSAL EVALUATION AND SELECTION 4.1 Evaluation and Selection Process All proposals will be initially screened to determine their compliance to the eligibility (section 3.0) and proposal instructions (section 5.0) of this Announcement. Proposals that do not comply may be declared noncompliant and rejected without further review. A submission compliance checklist is provided in section 5.0. This checklist provides proposers a list of the items that NASA will check for compliance before releasing a proposal for evaluation. Proposals deemed in compliance with this Announcement will be assessed against the evaluation criteria outlined in Section 4.2 by the Selection Recommendation Committee. Proposed collaborators should be aware that during the evaluation and selection process, NASA may request clarification of a specific point or points in a proposal. Such a request and the proposed collaborator's response shall be in writing. NASA reserves the right to suggest collaboration between proposers where it will enhance the effort, in which case proposers will be given the opportunity to accept or decline participation with other proposers prior to selection. The Selection Recommendation Committee members will conduct independent assessments of the proposals according to evaluation criteria outlined in Section 4.2. 4.2 Evaluation Criteria The evaluation factors below are of equal weighting during evaluation. Factor 1: Approach to Proposed Effort: The overall merit, rationale, feasibility, and suitability of the proposed effort or concept and its relevance to R&D that access to the ISS provides. Highest priority will be placed on an approach or concept that will create substantial increases in the current state-of-the-art. Describe how the proposer proposes to receive resulting data and/or samples from orbit. Factor 2: Level of Benefit to the Public: The proposed effort or concept's anticipated benefit to the public, in terms such as development of future products and services, and contribution to U.S. industrial capacity and/or economic growth. Factor 3: Level of Financial Commitment and Business Plan: The description of the level of financial commitments supporting the proposed efforts, including any third party financing required. Include a brief business plan for the proposed efforts or describe how the proposed efforts contribute to existing business plans. Identify the non-U.S. Government market potential for the R&D efforts. The proposed space activity is essential to product research, development, or processing, and is targeted to an addressable market. A roadmap exists; it includes the essential activities to bring the product to market beyond the development space activities. In addition, describe all cargo to be transported between Earth and the ISS that your proposed efforts require and how your business plan addresses meeting those requirements including any sample return and disposition of the on-orbit equipment/payloads. In addition, NASA reserves the right to assess information outside the proposal as it relates to the factors listed above. 4.3 Selection Factors As described in Section 4.1, the results of the proposal evaluations based on the criteria above and the subsequent Selection Recommendation Committee deliberations will be considered in the selection process. The Selection Recommendation Committee may take into account a variety of programmatic factors in deciding whether or not to select any proposals, including, but not limited to, available on-orbit resources, and compatibility to the ISS. The Selection Authority shall be the Associate Administrator for Space Operations. The Selection Authority will make the final selection of those approved for this opportunity after the completion of negotiations, depending on the outcome of the negotiations. 4.4 Selection Notification NASA will notify all proposed collaborators of the results of the evaluation and selection process. Selection does not guarantee a launch opportunity. Selection does guarantee NASA will provide the on orbit resources and trained crew to perform the experiment once it is on board. After the completion of the evaluation and selection process, NASA will begin negotiations with the selected proposer(s). The purpose of the negotiations is to define the terms and conditions of the Agreement supporting the participation of the proposers and to align the selected proposals with the anticipated on-orbit resource availability. All work will commence after the parties execute the Space Act Agreement. 5.0 PROPOSAL INSTRUCTIONS Proposals must comply with the following requirements. Page Limitations Proposal Section - Total Pages Proposal Cover Page - 1 Proposal Title Page - 1 Points of Contact - 1 Proposal Abstract - 750 words Proposal Detail - 10 Appendix Resumes - No Page Limit Additional Documentation - No Page Limit Pages in excess of the page limitations for each section will not be evaluated. A page is defined as one (1) sheet 8 x 11 inches using a minimum of 12-point font size for text and 8-point for graphs. There is no limit on appendix documentation. The intent is to allow proposals to include current documentation in its current format without having to alter any documents. The proposal must include the following sections, in this order: Proposal Cover Page: Solicited Proposal Application - Title of Announcement and Proposal Contact Information. An optional graphic image may be included. Proposal Title Page, with Notice of Restriction on Use and Disclosure of Proposal Information, if any. Points of Contact: List contact information for all Points of Contact including a Technical Point of Contact. Provide: a. Name b. Title c. Address d. Phone and Fax e. Email Proposal Abstract: Executive summary describing the prominent and distinguishing features of the proposal. Proposal Detail: The proposal shall contain sufficient information to enable reviewers to make informed judgments to assess the three criteria of the proposed effort. Proposal Appendix: * Resumes o Resumes may be included for key personnel. In general, resumes should be limited to no more than 1-2 pages each. * Additional documentation Include any documentation in the appendix that validates or supports the proposal Compliance checklist and required documents o The proposer is a domestic entity other than U.S. federal government agency o Proposal includes demonstration of the overall merit, rationale, feasibility, and suitability that access to the ISS provides o Proposal includes a description of the level of benefit to the public o Proposal includes a description of the level of financial commitment and business plan o Proposal includes a schedule for remaining development required before flight o Proposal includes a management/ project plan for remaining development o Proposal includes funding commitment letters demonstrating sufficient financial support for remaining development or financial milestones required to complete development

rolling
other

Free to search & build · $99 one-time to unlock the application pack · No subscription

Network Proximity-based Drug Repurposing in COPD

open

NHLBI - National Heart Lung and Blood Institute

PROJECT SUMMARY Chronic obstructive pulmonary disease (COPD) is a leading cause of death worldwide and a major driver of healthcare costs, yet few new therapies have emerged in recent decades. Repurposing existing drugs offers a faster, lower-cost path to treatment; repurposed agents succeed at three times the rate of de novo drugs. Further, drug candidates are twice as likely to be approved when supported by genetic evidence. However, the path to repurposing is often serendipitous rather than systematic. Systematic approaches that utilize genetic and multiple omics data to identify and validate drug repurposing candidates for COPD have not been applied. This project combines network-based computational methods with real-world clinical data to accelerate COPD drug repurposing. In Aim 1, we will build an updated COPD “disease module” by integrating the latest genome- wide association studies and multi-omics data into the human protein interactome. Using a proximity-based framework and hypothesis testing, we will identify drugs whose targets lie closest to COPD-related networks and prioritize those expressed in lung tissue and relevant immune cells. In Aim 2, we will perform comparative effectiveness studies in the Merative Marketscan dataset (>100 million covered lives) to test whether candidate drugs are associated with reduced COPD exacerbations compared to matched referent therapies using state- of- the-art methods for confounding control and causal inference. The expected outcomes include: (1) an updated COPD network module and publicly available web platform for continued repurposing efforts; (2) identification of promising drug candidates with biological plausibility; and (3) prioritization of agents for early-phase clinical trials. This project is innovative in systematically uniting genetics, omics, and network science with pharmacoepidemiology, and significant in contributing to a low-cost, scalable pipeline for drug repurposing in COPD. The work will generate critical preliminary data for subsequent R01 and clinical trial proposals, with the goal of expanding effective treatment options for millions of patients with COPD.

Up to $373K
2028-08-14
health research

Free to search & build · $99 one-time to unlock the application pack · No subscription

Neural circuit mechanisms of inflexible drug seeking in a model of HIV infection

open

NIDA - National Institute on Drug Abuse

Project Summary Human immunodeficiency virus (HIV) infection frequently co-occurs with cocaine use disorder (CUD). Despite high rates of psychostimulant use among people living with HIV (PLWH), and the worsening of HIV outcomes by chronic drug exposure - including increased risk for neurocognitive impairment -, targeted therapeutic strategies to reduce drug use in PLWH are lacking. CUD is characterized by difficulty in terminating drug use and high propensity to relapse after even protracted abstinence. This can be modeled in rodents through extinction learning (persistent drug seeking) and reinstatement (relapse to use) models. Extinction and reinstatement are mediated in part by projections to the nucleus accumbens shell (NAcS) from the infralimbic subregion of the medial prefrontal cortex (IL). HIV infection and chronic drug exposure have independent and interactive effects on the brain and behavior, including regulation of reward seeking. Our previous and preliminary findings identify impaired extinction learning in multiple mouse models of HIV infection (humanized mouse model with HIV-1 infection and wild-type mice with EcoHIV infection). We further observe increased cocaine-primed reinstatement in the EcoHIV model. These behavioral changes are accompanied by dysregulation of the IL and NAc. Thus, this proposal will apply in vivo electrophysiology, tract tracing, and circuit-specific chemogenetics to test the overarching hypothesis that EcoHIV infection impacts activity in glutamatergic projections from the IL to the NAcS and that modulation of these projections is sufficient to suppress drug seeking in animals with EcoHIV infection. We propose that alterations in these circuits resulting from infection impair cognitive control of behavior which promotes the maintenance of and susceptibility to relapse to cocaine seeking. Aim 1 will determine the effects of EcoHIV and/or ART on IL encoding of cocaine reward and seeking behavior using in vivo electrophysiology to track neuronal activity across behavior. This Aim will further assess interactive effects of EcoHIV and/or ART exposure with a history of cocaine administration on later neurocognitive performance. Aim 2 will investigate the ability of modulation of ILNAcS circuit activity to suppress cocaine reinstatement in EcoHIV-infected mice. This will be accomplished using chemogenetic modulation of the IL and of IL projections to the NAcS and through local administration of an mGluR2/3 agonist to the NAc. Aim 3 will test the effects of EcoHIV and/or ART on cocaine-associated alterations in activity within IL to NAc circuitry. This will be accomplished using multiplexed tract tracing and immunofluorescent labeling. This Aim will further identify EcoHIV and ART effects on glutamate receptor expression within the prefrontal cortex and NAC using western blot. Together, the results of these experiments will inform the mechanisms by which EcoHIV alters cocaine seeking and taking behavior and expand our understanding of the circuit-level consequences of EcoHIV infection which may support next- generation CUD and HAND therapeutic development for PLWH.

Up to $446K
2031-02-28
health research

Free to search & build · $99 one-time to unlock the application pack · No subscription

Neurodevelopmental Disorders: Mechanisms and Therapeutics

open

NINDS - National Institute of Neurological Disorders and Stroke

Abstract Support is requested for a Keystone Symposia conference entitled Neurodevelopmental Disorders: Mechanisms and Therapeutics, organized by Drs. Tomasz Nowakowski, Xin Jin, Stephan Sanders and Zhaolan (Joe) Zhou, with scientific programming input from Keystone Symposia. The meeting will take place January 19-22, 2027 at Beaver Run Conference Center, Breckenridge, CO. Neurodevelopmental disorders (NDDs), including autism, intellectual disability, and epilepsy, arise from disruptions during brain development and pose major challenges to public health. Although advances in genetics have identified hundreds of causal genetic risk factors, identifying convergent mechanisms underlying their pathobiology remains a challenge, which hinders the development of personalized therapies. This meeting addresses the critical gap between emerging insights into causal factors, neurodevelopment, and therapeutic innovation by uniting experts across basic and translational neuroscience. The proposed conference will foster new collaborations between investigators in genetics, functional genomics, developmental neurobiology, and industry. Specific aims include showcasing breakthroughs in single-cell genomics, genome perturbation technologies, gene-environment interactions, and novel therapeutic strategies such as gene replacement therapies and antisense oligonucleotides (ASOs). The program is designed to challenge prevailing hypotheses towards understanding NDDs by taking a holistic perspective on molecular, cellular, and circuit level mechanisms underlying brain development and their vulnerabilities to genetic and environmental risk factors for NDDs. By integrating state-of-the-art technologies into biologically driven sessions, the conference will emphasize translational pathways from discovery of causal risk factors to clinical impact. Attendees will gain exposure to innovative methodologies, mechanistic frameworks, and considerations for clinical trials, thereby advancing the field toward tangible treatments. Unlike existing meetings that focus separately on neurodevelopment, stem cell models or therapeutic pipelines, this conference uniquely fuses mechanistic understanding of genetic and environmental causes with translational application. Interactive sessions, panel discussions, and strong industry participation make this a pivotal forum for scientists seeking to shape the next generation of neurodevelopmental disorder research.

Up to $10K
2027-07-31
health research

Free to search & build · $99 one-time to unlock the application pack · No subscription

Neurovascular Imaging Across Scales in Animals and Humans

open

NINDS - National Institute of Neurological Disorders and Stroke

There have been great advances in microscopic and non-invasive optical neuroimaging technologies, which allow neuroscientists to visualize molecular, cellular and systems-level brain physiology and functions. For the last five years, these technological efforts have been greatly facilitated by the BRAIN Initiative, which also supports the pipeline to commercialization. However, this fast growth has widened the gap between the developers and the neuroscience community in need. This is because to properly use these novel tools, it is important to understand the underlying physical principles and have the practical skills in data collection and analysis. Furthermore, each technique comes with its limitations, and understanding these limitations is critical for avoiding unconscious bias. Thus, although instrumentation may be available, the researchers are often not fully utilizing these tools due to the lack of proper training. To this end, we propose a two-week Summer School program in Neurovascular Imaging Across Scales in Animals and Humans run by the Boston University (BU) Neurophotonics Center. This program will offer hands- on, practical training in a number of optical imaging technologies applicable to in vivo studies in awake behaving animals. In addition, we include a macroscopic, non-invasive optical imaging modality applicable to humans. These technologies will be taught and exemplified in the context of specific neuroscience questions developed by trainees. These questions will be centered on neurovascular brain physiology in heath and disease addressing the mission of NINDS. The program will target graduate students and postdoctoral fellows in the beginning of their research projects who started using one of these imaging technologies and want to acquire practical “know-how” skills and gain exposure to other imaging technologies applicable to neurovascular studies. Our primary goal is to create an innovative educational program using neurophotonics as an enabler to understand neurovascular brain function in health and disease. This program will also contribute to broad dissemination of neurophotonics technologies, increase visibility of these tools within the neuroscience community, and promote the emerging interdisciplinary field of neurophotonics and the deliverables of the BRAIN Initiative. The program alumni will fill an acute nation-wide need for neuroscience investigators skilled in state- of-the-art neurophotonics technologies. In addition, we expect the key aspects of our innovative training approach to be translated to other interdisciplinary graduate and postgraduate education programs at BU and beyond. Our best practices and measured impacts of experiential learning will be disseminated to peer institutions and to graduate education stakeholders. Our primary goal is to create an innovative educational program using neurophotonics as an enabler to understand neurovascular brain function in health and disease. This program will also contribute to broad dissemination of neurophotonics technologies, increase visibility of these tools within the neuroscience community, and promote the emerging interdisciplinary field of neurophotonics and the deliverables of the BRAIN Initiative. The program alumni will fill an acute nation-wide need for neuroscience investigators skilled in state- of-the-art neurophotonics technologies. In addition, we expect the key aspects of our innovative training approach to be translated to other interdisciplinary graduate and postgraduate education programs at BU and beyond. Our best practices and measured impacts of experiential learning will be disseminated to peer institutions and to graduate education stakeholders.

Up to $250K
2031-01-31
health research

Free to search & build · $99 one-time to unlock the application pack · No subscription

Neutralizing and FcR-mediating antibody specificities and function in control of HHV-8 infection

open

NIAID - National Institute of Allergy and Infectious Diseases

PROJECT SUMMARY/ABSTRACT Kaposi’s Sarcoma (KS), driven by Kaposi’s Sarcoma-associated Herpesvirus (KSHV), remains a leading AIDS- associated malignancy and a growing concern among immunocompromised populations, including people living with HIV (PLWH) and solid organ transplant recipients. Despite effective antiretroviral therapy (ART), KS can still emerge in individuals with suppressed HIV viral loads and preserved CD4+ T cell counts, underscoring an unmet critical need for immune interventions beyond ART and T cell-mediated control. One promising strategy involves harnessing antibodies capable of recruiting effector cells to eliminate infected cells. Results from preclinical vaccine studies and clinical trials indicate that Fc-mediated effector function of antibodies significantly contribute to overall antibody efficacy in treatment and prevention of numerous carcinogenic viral infections. However, there remains a gap in our knowledge regarding the role of antibodies with Fc-mediated effector functions in controlling KSHV in immunocompromised population. This proposal will leverage the rhesus macaque rhadinovirus (RRV)/rhesus macaque (RM) model, which closely mimics KSHV infection, to investigate the capacity of antibodies with Fc-mediated functions to recruit effector cells and suppress RRV reactivation following SIV co- infection. Specifically, we will compare antibody responses during primary RRV infection and following RRV reactivation due to SIV co-infection; assess whether RRV reactivation drives B cell maturation capacity of producing Fc-functional antibodies; and evaluate the efficacy of these antibodies in immunocompromised animals to prevent RRV reactivation. Our central hypothesis is that KSHV-specific antibodies with Fc-mediated functions are critical for controlling KSHV infection, and their presence during immune suppression will prevent KSHV reactivation and KS development. Preliminary data supports this hypothesis, demonstrating that plasma from RRV-infected RMs contains antibodies both recognize infected cells and exhibit Fc-mediated effector functions. The scientific premise in this K01 is that characterizing RRV-specific antibodies capable of recruiting NK cells and monocytes will inform future KSHV immunotherapies for PLWH. At the completion of the proposed research, my expected outcomes are two-fold: 1) scientific achievements: understanding of KSHV-specific humoral responses in presence of HIV co-infection in NHP model; and 2) career development: to gain knowledge and skills for leading a preclinical and translational research program using NHP models to develop and test vaccines and immunoprophylaxis strategies in the field of AIDS-associated malignancies.

Up to $211K
2031-05-31
health research

Free to search & build · $99 one-time to unlock the application pack · No subscription

Neutralizing persistent IFN-I to improve HIV-specific CAR T cell therapy

open

NIAID - National Institute of Allergy and Infectious Diseases

PROJECT SUMMARY A critical hurdle to further improving the quality of life for people living with HIV (PLWH) is the need to resolve the residual immune activation and inflammation that persists even in those taking effective antiretroviral therapy (ART), which suppresses HIV replication. This unresolved and persistent immune activation is associated with increased type-I interferon (IFN-I) signaling, and increased incidence of comorbidities. Encouragingly, reports demonstrate that blocking IFN-I signaling in animal models of HIV infection can reduce HIV reservoirs and restore T cell immune function. We hypothesize that blocking IFN-I would likewise augment engineered T cell-based therapies against HIV, such as chimeric antigen receptor (CAR) T cells. Our prior work has demonstrated that when engineered to express both the 4-1BB and CD28 costimulatory domains and protected from HIV infection, HIV-specific CD4 ectodomain CAR T cells can reduce acute viremia, prevent CD4+ T cell loss, and reduce viral burden in the tissues of HIV-infected humanized mice. However, the reduction of plasma viral loads was ultimately transient, suggesting that the potency of HIV-specific CAR T cells should be further optimized for clinical translation. Our preliminary data highlights interferon-beta (IFNb) as a key immunosuppressive IFN-I negatively regulating CAR T cell proliferation, and we demonstrate that neutralizing IFNb in vivo enhanced the engraftment and persistence of HIV-specific CAR T cells adoptively transferred into HIV-infected ART- suppressed humanized mice. This proposal will interrogate whether IFNb neutralization augments CAR T cell therapy through 1) identifying the mechanism(s) by which chronic IFNb exposure mediates HIV-specific CAR T cell dysfunction, and 2) determining the effect of neutralizing IFNb on CAR T cell function and persistence in HIV infection in vivo. The proposed aims seek to develop the neutralization of IFNb as a novel immunotherapy approach to maximize the potency of HIV-specific CAR T cells aimed at achieving a functional HIV cure.

Up to $507K
2028-05-31
health research

Free to search & build · $99 one-time to unlock the application pack · No subscription

FindGrants Pro

Save unlimited matches with FindGrants Pro — $19/mo

Includes 1 application credit per month, weekly emailed grant alerts matching your org, and deadline reminders. Cancel anytime.

See Pro details

Found a grant that fits? Get matched to even more.

Answer a 2-minute questionnaire and our engine scores every grant in the database against your organization — surfacing opportunities you might miss browsing manually.

Get Personalized Matches — Free